volume 136, issue Supplement 1, P42-42 2020
DOI: 10.1182/blood-2020-134150
View full text
|
|
Share

Abstract: Background: Multiple myeloma (MM) accounts for 10% of all hematological malignancies. This has prompted the introduction of significant therapeutic advancements, such as novel agents and autologous stem cell transplants, resulting in drastic improvement in the disease prognosis. The National Cancer Institute reported a 49% improvement in 5-year relative survival rates of MM from 2005 to 2011 compared to just 27% from 1987 to 1989. However, existing literature has identified socioeconomic barriers in receiving …

expand abstract